Last reviewed · How we verify

DPT-IPV-Hib-High（Combined Vaccine）

Tanabe Pharma Corporation · Phase 3 active Biologic

DPT-IPV-Hib-High（Combined Vaccine） is a Pentavalent inactivated vaccine Biologic drug developed by Tanabe Pharma Corporation. It is currently in Phase 3 development for Prevention of diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b infection in infants and children. Also known as: BK1310-High.

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b.

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b. Used for Prevention of diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b infection in infants and children.

At a glance

Generic nameDPT-IPV-Hib-High（Combined Vaccine）
Also known asBK1310-High
SponsorTanabe Pharma Corporation
Drug classPentavalent inactivated vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

DPT-IPV-Hib is a pentavalent inactivated vaccine that contains antigens from five pathogens. Upon administration, it triggers both humoral (antibody-mediated) and cell-mediated immune responses, leading to the production of protective antibodies against toxins and surface antigens of these bacteria and viruses. This provides immunological memory for long-term protection against these infectious diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DPT-IPV-Hib-High（Combined Vaccine）

What is DPT-IPV-Hib-High（Combined Vaccine）?

DPT-IPV-Hib-High（Combined Vaccine） is a Pentavalent inactivated vaccine drug developed by Tanabe Pharma Corporation, indicated for Prevention of diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b infection in infants and children.

How does DPT-IPV-Hib-High（Combined Vaccine） work?

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b.

What is DPT-IPV-Hib-High（Combined Vaccine） used for?

DPT-IPV-Hib-High（Combined Vaccine） is indicated for Prevention of diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b infection in infants and children.

Who makes DPT-IPV-Hib-High（Combined Vaccine）?

DPT-IPV-Hib-High（Combined Vaccine） is developed by Tanabe Pharma Corporation (see full Tanabe Pharma Corporation pipeline at /company/tanabe-pharma-corporation).

Is DPT-IPV-Hib-High（Combined Vaccine） also known as anything else?

DPT-IPV-Hib-High（Combined Vaccine） is also known as BK1310-High.

What drug class is DPT-IPV-Hib-High（Combined Vaccine） in?

DPT-IPV-Hib-High（Combined Vaccine） belongs to the Pentavalent inactivated vaccine class. See all Pentavalent inactivated vaccine drugs at /class/pentavalent-inactivated-vaccine.

What development phase is DPT-IPV-Hib-High（Combined Vaccine） in?

DPT-IPV-Hib-High（Combined Vaccine） is in Phase 3.

What are the side effects of DPT-IPV-Hib-High（Combined Vaccine）?

Common side effects of DPT-IPV-Hib-High（Combined Vaccine） include Injection site pain, redness, or swelling, Fever, Irritability or fussiness, Drowsiness.

Related